Analysis and reporting of adverse events in randomised controlled trials: a review

被引:134
|
作者
Phillips, Rachel [1 ]
Hazell, Lorna [2 ,3 ]
Sauzet, Odile [4 ]
Cornelius, Victoria [1 ]
机构
[1] Imperial Coll London, Fac Med, Sch Publ Hlth, London, England
[2] Drug Safety Res Unit, Clin Res, Southampton, Hants, England
[3] Univ Portsmouth, Dept Pharm & Biomed Sci, Portsmouth, Hants, England
[4] Univ Bielefeld, Epidemiol & Int Publ Hlth, Fac Hlth Sci, Bielefeld, Germany
来源
BMJ OPEN | 2019年 / 9卷 / 02期
关键词
CLINICAL-TRIALS; SAFETY DATA; THERAPY; ERYTHROPOIETIN; CHILDREN; INSULIN; ASPIRIN; PLACEBO;
D O I
10.1136/bmjopen-2018-024537
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To ascertain contemporary approaches to the collection, reporting and analysis of adverse events (AEs) in randomised controlled trials (RCTs) with a primary efficacy outcome. Design A review of clinical trials of drug interventions from four high impact medical journals. Data sources Electronic contents table of the BMJ, the Journal of the American Medical Association (JAMA), the Lancet and the New England Journal of Medicine (NEJM) were searched for reports of original RCTs published between September 2015 and September 2016. Methods A prepiloted checklist was used and single data extraction was performed by three reviewers with independent check of a randomly sampled subset to verify quality. We extracted data on collection methods, assessment of severity and causality, reporting criteria, analysis methods and presentation of AE data. Results We identified 184 eligible reports (BMJ n=3; JAMA n=38, Lancet n=62 and NEJM n=81). Sixty-two per cent reported some form of spontaneous AE collection but only 29% included details of specific prompts used to ascertain AE data. Numbers that withdrew from the trial were well reported (80%), however only 35% of these reported whether withdrawals were due to AEs. Results presented and analysis performed was predominantly on 'patients with at least one event' with 84% of studies ignoring repeated events. Despite a lack of power to undertake formal hypothesis testing, 47% performed such tests for binary outcomes. Conclusions This review highlighted that the collection, reporting and analysis of AE data in clinical trials is inconsistent and RCTs as a source of safety data are underused. Areas to improve include reducing information loss when analysing at patient level and inappropriate practice of underpowered multiple hypothesis testing. Implementation of standard reporting practices could enable a more accurate synthesis of safety data and development of guidance for statistical methodology to assess causality of AEs could facilitate better statistical practice.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis
    Monica Bolton
    Alex Hodkinson
    Shivani Boda
    Alan Mould
    Maria Panagioti
    Sarah Rhodes
    Lisa Riste
    Harm van Marwijk
    BMC Medicine, 17
  • [22] Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis
    Bolton, Monica
    Hodkinson, Alex
    Boda, Shivani
    Mould, Alan
    Panagioti, Maria
    Rhodes, Sarah
    Riste, Lisa
    van Marwijk, Harm
    BMC MEDICINE, 2019, 17 (1)
  • [23] CORTICOSTEROIDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REPORTED ADVERSE EVENTS IN RANDOMISED CONTROLLED TRIALS
    Major, Rupert
    Grant, Robert
    Nockels, Keith
    Das, Mrinal
    Floege, Juergen
    Barratt, Jonathan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [24] The quality of reporting of randomised controlled trials in asthma: a systematic review
    Ntala, Chara
    Birmpili, Panagiota
    Worth, Allison
    Anderson, Niall H.
    Sheikh, Aziz
    PRIMARY CARE RESPIRATORY JOURNAL, 2013, 22 (04): : 417 - 424
  • [25] Using serious adverse events to assess representativeness of randomised controlled trials
    Hanlon, Peter
    Corcoran, Neave
    Rughani, Guy
    Shah, Anoop
    Mair, Frances
    Guthrie, Bruce
    Renton, Joanne
    McAllister, David
    AUSTRALIAN JOURNAL OF PRIMARY HEALTH, 2021, 27 (04) : XX - XX
  • [26] A systematic review of outcome reporting in achalasia randomised controlled trials
    Gray, R. T.
    Kennedy, R.
    Kennedy, J. A.
    BRITISH JOURNAL OF SURGERY, 2016, 103 : 119 - 119
  • [27] Reporting of sample size calculation in randomised controlled trials: review
    Charles, Pierre
    Giraudeau, Bruno
    Dechartres, Agnes
    Baron, Gabriel
    Ravaud, Philippe
    BMJ-BRITISH MEDICAL JOURNAL, 2009, 338 : 1256
  • [28] Low quality of reporting adverse drug reactions in paediatric randomised controlled trials
    de Vries, Tjalling W.
    van Roon, Eric N.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2010, 95 (12) : 1023 - 1026
  • [29] ADVERSE EVENTS OF MAINTENANCE IMMUNOSUPPRESSION FOLLOWING KIDNEY TRANSPLANTATION REPORTED IN RANDOMISED CONTROLLED TRIALS: A SYSTEMATIC REVIEW
    Howell, M.
    Yeo, R.
    Tong, A.
    Craig, J. C.
    Howard, K.
    Wong, G.
    NEPHROLOGY, 2014, 19 : 50 - 50
  • [30] Methodology and reporting of randomised controlled trials
    Jacobs, WCH
    KNEE, 2004, 11 (06): : 423 - 425